About this Research Topic
In autoimmune diseases or transplant rejection, an exacerbated response to the graft or the self-develop. Another scenario of disproportionate immune response is the cytokine release syndrome (CRS), a systemic inflammatory response characterized by a sharp increase of proinflammatory cytokines triggered by factors such as infections, drugs, chimeric antigen receptor T cell (CAR-T) therapy in oncologic patients, or GvHD. There are over 150 rare inflammatory/autoimmune diseases, many of which are incurable and terminal. The standard treatment to prevent these hyper-immune responses is the use of immunosuppressive drugs or immunoglobulins, but they still do not provide a definitive solution and produce side effects that are decisive in the patient's clinical course. Those pathologies have wide variability, and different causative and pathogenic processes, making the current treatment strategies fall short of the expected complete remission.
In the last decade, various gene and cell therapy approaches have been under development, showing promising efficient and specific outcomes. This Special Issue aims to recompile emerging therapeutic approaches against a wide range of inflammatory disorders that could be useful to treat chronic and acute inflammations, autoimmune diseases, or avoiding graft rejection. Newly developed biologics are now in the clinical phase and include antibody therapies, vaccines, gene therapies, and cell therapies. Those approaches permitted the improvement of the life-threatening inflammation, symptomatology, and quality of life of patients. However, non-responders are patients who do not respond, insufficiently respond to treatment, or lose clinical response over time. Thus, alternative therapies such as personalized medicine are urgently needed.
Due to cutting-edge technologies and models available, innovative approaches are in progress. In this special issue, we welcome submissions of original research articles, reviews, and meta-analyses of clinical trials covering, but not limited to:
1. Determination of basic mechanisms to treat inflammatory/autoimmune diseases/transplant rejection
2. Development of new and promising complementary strategies to diagnose those pathologies
3. Description of novel Gene and Cell therapies developed to treat immune system hyperactivation
4. Description of novel immunotherapies such as, but not limited to, aptamers, extracellular vesicles, loaded lipid nanoparticles, faecal transplant, radiopharmaceuticals or small nucleic acids.
5. New biomarkers associated with the efficiency of those developed alternative approaches.
6. New and non-invasive techniques or tools for monitoring the results of the treatments.
7. Determination of potential new therapeutic targets.
8. Novel pre-clinical models to measure the efficiency and pharmacokinetics of the new immunotherapeutic drugs.
Bibliometric studies are outside of the scope of this topic and may be rejected or redirected to other journals or sections as appropriate. Bioinformatics or Computational Analysis of public genome or transcriptome databases need to be accompanied by robust and relevant validation to be submitted to this topic. Manuscripts describing the pharmacological action of drugs used in traditional medicine in models of disease, such as inflammatory disease, are not in scope unless they have a strong focus on the immune system.
Topic Editor Dr. Marjorie Pion is the co-founder of THYTECH SL. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
In the last decade, various gene and cell therapy approaches have been under development, showing promising efficient and specific outcomes. This Special Issue aims to recompile emerging therapeutic approaches against a wide range of inflammatory disorders that could be useful to treat chronic and acute inflammations, autoimmune diseases, or avoiding graft rejection. Newly developed biologics are now in the clinical phase and include antibody therapies, vaccines, gene therapies, and cell therapies. Those approaches permitted the improvement of the life-threatening inflammation, symptomatology, and quality of life of patients. However, non-responders are patients who do not respond, insufficiently respond to treatment, or lose clinical response over time. Thus, alternative therapies such as personalized medicine are urgently needed.
Due to cutting-edge technologies and models available, innovative approaches are in progress. In this special issue, we welcome submissions of original research articles, reviews, and meta-analyses of clinical trials covering, but not limited to:
1. Determination of basic mechanisms to treat inflammatory/autoimmune diseases/transplant rejection
2. Development of new and promising complementary strategies to diagnose those pathologies
3. Description of novel Gene and Cell therapies developed to treat immune system hyperactivation
4. Description of novel immunotherapies such as, but not limited to, aptamers, extracellular vesicles, loaded lipid nanoparticles, faecal transplant, radiopharmaceuticals or small nucleic acids.
5. New biomarkers associated with the efficiency of those developed alternative approaches.
6. New and non-invasive techniques or tools for monitoring the results of the treatments.
7. Determination of potential new therapeutic targets.
8. Novel pre-clinical models to measure the efficiency and pharmacokinetics of the new immunotherapeutic drugs.
Bibliometric studies are outside of the scope of this topic and may be rejected or redirected to other journals or sections as appropriate. Bioinformatics or Computational Analysis of public genome or transcriptome databases need to be accompanied by robust and relevant validation to be submitted to this topic. Manuscripts describing the pharmacological action of drugs used in traditional medicine in models of disease, such as inflammatory disease, are not in scope unless they have a strong focus on the immune system.
Topic Editor Dr. Marjorie Pion is the co-founder of THYTECH SL. The other Topic Editors declare no competing interests with regard to the Research Topic subject.
Keywords: gene cell therapies, hyperinflammatory diseases
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
